ViroGates A/S announced that the distribution partner in Germany bestbion dx GmbH has started successful selling suPARnostic® for clinical use, to guide anakinra treatment in adult COVID-19 patients, in several hospitals in the German market. ViroGates are supplying products to bestbion dx on a centralized basis and cannot inform of details of the individual accounts.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.34 DKK | +7.31% | -0.54% | +21.93% |
1st Jan change | Capi. | |
---|---|---|
+21.93% | 6.36M | |
-27.67% | 9.87B | |
-17.30% | 2.74B | |
-11.15% | 2.24B | |
-22.32% | 1.63B | |
+59.69% | 1.39B | |
+23.58% | 772M | |
-1.31% | 760M | |
-28.57% | 516M | |
+5.37% | 310M |
- Stock Market
- Equities
- VIRO Stock
- News ViroGates A/S
- ViroGates A/S Announces bestbion dx GmbH as Distribution Partner in Germany